Austrian Hypertrophic Cardiomyopathy Registry

November 27, 2025 updated by: Nicolas Dominik Verheyen, MD, Medical University of Graz
The Austrian Hypertrophic Cardiomyopathy (HCM) Registry is a prospective, multicenter registry enrolling patients at multiple outpatient clinics across Austria including academic and non-academic centers. Patients will undergo a structured examination process including assessment for symptoms of HCM, past medical history, concomitant medication, family history and the presence of HCM-specific red flags. Furthermore, clinical data derived from electrocardiogram, echocardiography, laboratory analysis, and genetic testing will be collected focusing on a lean variable dictionary and, in addition, specific hypothesis-driven research parameters. All data are entered into an electronic case report form (eCRF) (Phoenix Clinical Trial Management System). In order to perform multicenter analyses, data can be extracted from the eCRF after approval by the steering committee.

Study Overview

Status

Recruiting

Conditions

Detailed Description

The Austrian Hypertrophic Cardiomyopathy (HCM) Registry is a prospective, multicenter registry enrolling patients at multiple outpatient clinics across Austria including academic and non-academic centers. Patients will undergo a structured examination process including assessment for symptoms of HCM, past medical history, concomitant medication, family history and the presence of HCM-specific red flags. Furthermore, clinical data derived from electrocardiogram, echocardiography, laboratory analysis, and genetic testing will be collected focusing on a lean variable dictionary and, in addition, specific hypothesis-driven research parameters. All data are entered into an electronic case report form (eCRF) (Phoenix Clinical Trial Management System). Every site will nominate one representative for the steering committee which will serve as the regulatory authority with the compentence to approve research and funding proposals.

The Austrian multicenter HCM Registry aims to facilitate a wide range of innovative cross-sectional and longitudinal epidemiological analyses unravelling gaps in evidence in HCM. The standardized clinical assessment might harmonize standards of clinical care in HCM patients in Austria.

Study Type

Observational

Enrollment (Estimated)

1000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Austria
      • Sankt Johann in Tirol, Austria, 6380
      • Wels-Grieskirchen, Austria, 4600
    • Linz
    • Lower Austria
      • Sankt Pölten, Lower Austria, Austria, 3100
      • Wiener Neustadt, Lower Austria, Austria, 2700
        • Recruiting
        • Hospital Landesklinikum Wiener Neustadt
        • Contact:
          • Martin Grübler, MD
          • Phone Number: martin.gruebler@gmx.net
    • Salzburg
      • Salzburg, Salzburg, Austria, 5020
        • Recruiting
        • Paracelsus Medical University of Salzburg
        • Contact:
      • Schwarzach im Pongau, Salzburg, Austria, 5620
    • Styria
      • Graz, Styria, Austria, 8036
        • Recruiting
        • Medical University of Graz
        • Sub-Investigator:
          • Nora Schwegel, MD
        • Contact:
        • Contact:
        • Principal Investigator:
          • Nicolas D Verheyen, MD, PHD
        • Sub-Investigator:
          • Viktoria Santner, MD
      • Graz, Styria, Austria, 8020
    • Tyrol
    • Upper Austria
      • Braunau am Inn, Upper Austria, Austria, 5280
      • Linz, Upper Austria, Austria, 4020
    • Vienna
      • Vienna, Vienna, Austria, 1090
      • Vienna, Vienna, Austria, 1100
        • Active, not recruiting
        • Favoriten Clinic Vienna
      • Vienna, Vienna, Austria

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

The study population includes subjects who fulfill criteria of HCM and are treated in Austria.

Description

Inclusion Criteria:

  • Patients admitted to the HCM outpatient clinic of participating centers of the HCM Registry
  • Interventricular septal thickness ≥ 13 mm and cardiomyopathy-specific red flags OR Interventricular septal thickness ≥ 15 mm not explainable by loading conditions OR Interventricular septal thickness ≥ 17 mm
  • Willingness and ability to provide signed informed consent form (ICF) prior to participation in any study-related procedures

Exclusion criteria:

  • Age < 18 years
  • Known cardiac amyloidosis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
All cause mortality
Time Frame: Through study completion, on average 20 years
All cause mortality
Through study completion, on average 20 years
Cardiovascular events
Time Frame: Through study completion, on average 20 years
Cardiovascular events
Through study completion, on average 20 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Medical University of Graz

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 8, 2024

Primary Completion (Estimated)

March 1, 2044

Study Completion (Estimated)

March 1, 2044

Study Registration Dates

First Submitted

April 10, 2024

First Submitted That Met QC Criteria

April 12, 2024

First Posted (Actual)

April 16, 2024

Study Record Updates

Last Update Posted (Actual)

December 5, 2025

Last Update Submitted That Met QC Criteria

November 27, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ID01/2024/MZHCM-Reg/NV

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypertrophic Cardiomyopathy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe